Ali S Alzahrani1,2,3, Dania Alkhafaji1, Mahmoud Tuli4, Hindi Al-Hindi5, Bakr Bin Sadiq3. 1. Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 2. Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 3. Research Center-Jeddah, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 4. Department of Medical Imaging, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 5. Department of Pathology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Abstract
CONTEXT: Age is a major prognostic factor in differentiated thyroid cancer (DTC). It is not clear if paediatric DTC has a different histopathological profile and outcome than DTC in adult patients <45 years of age. OBJECTIVE: To assess whether DTC in children and adolescents differs from young age group by comparing paediatric DTC (age ≤ 20) with DTC in patients >20 to <45 years of age. PATIENTS AND METHODS: We studied all cases of paediatric DTC seen during the period 1998-2011. We compared this group with a large sample of 213 consecutive adult patients in the age group >20 to <45 years seen during the period 1998-1999 in terms of their pathological features, extent of the disease and long-term outcome. Both groups were managed by the same team at a single institution. RESULTS: A total of 310 DTC were studied including 97 paediatric patients [median age 17 years (range, 8-20)] and 213 young adult patients [median age 33 years (range, 20·5-44·9)]. There was no difference in gender distribution, tumour subtypes, size and tumour multifocality, but there was a significantly higher rate of extrathyroidal extension [40/75 (53·3%) vs 81/213 (38·0%), P = 0·03], lymph node [57/73 (78%) vs 102/183 (55·7%), P < 0·0001] and distant metastases [16/97 (16·5%) vs 8/213 (3·8%), P < 0·0001] in the paediatric than the adult groups. Kaplan-Meier analysis showed a higher risk of persistent/recurrent disease in the paediatric group than adults (log-rank test 0·03). However, there was no mortality secondary to DTC in both groups. CONCLUSION: Paediatric DTC is distinct from DTC in the young adults (age >20 to <45 years). It is characterized by a higher rate of extrathyroidal extension, lymph node and distant metastases and a higher risk of persistent/recurrent DTC.
CONTEXT: Age is a major prognostic factor in differentiated thyroid cancer (DTC). It is not clear if paediatric DTC has a different histopathological profile and outcome than DTC in adult patients <45 years of age. OBJECTIVE: To assess whether DTC in children and adolescents differs from young age group by comparing paediatric DTC (age ≤ 20) with DTC in patients >20 to <45 years of age. PATIENTS AND METHODS: We studied all cases of paediatric DTC seen during the period 1998-2011. We compared this group with a large sample of 213 consecutive adult patients in the age group >20 to <45 years seen during the period 1998-1999 in terms of their pathological features, extent of the disease and long-term outcome. Both groups were managed by the same team at a single institution. RESULTS: A total of 310 DTC were studied including 97 paediatric patients [median age 17 years (range, 8-20)] and 213 young adult patients [median age 33 years (range, 20·5-44·9)]. There was no difference in gender distribution, tumour subtypes, size and tumour multifocality, but there was a significantly higher rate of extrathyroidal extension [40/75 (53·3%) vs 81/213 (38·0%), P = 0·03], lymph node [57/73 (78%) vs 102/183 (55·7%), P < 0·0001] and distant metastases [16/97 (16·5%) vs 8/213 (3·8%), P < 0·0001] in the paediatric than the adult groups. Kaplan-Meier analysis showed a higher risk of persistent/recurrent disease in the paediatric group than adults (log-rank test 0·03). However, there was no mortality secondary to DTC in both groups. CONCLUSION: Paediatric DTC is distinct from DTC in the young adults (age >20 to <45 years). It is characterized by a higher rate of extrathyroidal extension, lymph node and distant metastases and a higher risk of persistent/recurrent DTC.
Authors: Ji Young You; Se-Woong An; Hoon Yub Kim; Da Won Park; Hyung Kwon Byeon; Serena Patroniti; Gianlorenzo Dionigi; Ralph P Tufano Journal: Front Pediatr Date: 2022-04-28 Impact factor: 3.569
Authors: Kwangsoon Kim; Won Woong Kim; Jung Bum Choi; Min Jhi Kim; Cho Rok Lee; Jandee Lee; Sang-Wook Kang; Kee-Hyun Nam; Woong Youn Chung; Jong Ju Jeong Journal: Ann Surg Treat Res Date: 2018-09-28 Impact factor: 1.859
Authors: Raad Alwithenani; Sarah DeBrabandere; Irina Rachinsky; S Danielle MacNeil; Mahmoud Badreddine; Stan Van Uum Journal: J Thyroid Res Date: 2019-06-02
Authors: Soo Young Kim; Hyeok Jun Yun; Hojin Chang; Seok-Mo Kim; Soyoung Jeon; Sujee Lee; Yong Sang Lee; Hang-Seok Chang; Cheong Soo Park Journal: Front Oncol Date: 2022-04-26 Impact factor: 5.738
Authors: Maria Isabel C V Cordioli; Lais Moraes; Gianna Carvalheira; Luiza Sisdelli; Maria Teresa S Alves; Rosana Delcelo; Osmar Monte; Carlos A Longui; Adriano N Cury; Janete M Cerutti Journal: Cancer Med Date: 2016-03-31 Impact factor: 4.452